One Health Studio:
Digital Twin of Human Pathophysiology

OneHealthStudio leverages mechanistic systems modeling empowered by SciML to predict effects on human organs, accelerating drug development while reducing reliance on animal testing.

NGRA
Next Generation Risk Assessment (NGRA) integrates computational and in-vitro approaches to evaluate chemical safety without animal testing.
MIDD
Model-Informed Drug Development (MIDD) uses quantitative models to inform drug development and regulatory decisions across all stages.
siRNA
choose a case study
Hover over organ for details.